About DKMS

ABOUT US

Our story begins in 1991, when our founder, Dr. Peter Harf, lost his wife Mechtild to leukemia. Peter promised his wife to help everyone in need of a stem cell donation to find a matching donor. At that time, there were only 3,000 potential stem cell donors available in Germany. Peter founded DKMS Germany, and within just one year the number of potential donors increased to 68,000. This was reason enough for our founder to believe in his vision – to delete blood cancer and give everyone in need of a stem cell donation a second chance at life. In 2004, we embarked on our international journey by founding DKMS in the US, followed by further openings in Poland in 2009, the UK in 2013 and Chile in 2018. Every 35 seconds, someone somewhere in the world is diagnosed with blood cancer. DKMS gives hope to those in need of a stem cell donation, by providing people all around the world with a second chance at life. An international exchange system ensures that the search for a matching stem cell donor is carried out globally and if necessary, the stem cell donation crosses borders. 41% of all stem cell donations worldwide are enabled by DKMS. To work towards our goal of finding a matching donor for everyone in need of a stem cell donation, we need to continue to grow and register potential donors from all over the world. Every day, over 850 DKMS employees around the world are committed to giving more people in need of a stem cell donation a second chance at life.

Our vision and Mission

VISION DKMS: WE ARE FIGHTING AGAINST BLOOD CANCER

We want to find a compatible donor for each patient with blood cancer or facilitate access to treatment, no matter where in the world it is.

MISSION DKMS: WE REGISTER DONORS OF STEM CELLS

We motivate people to register as a stem cell donor to give a second chance to life to patients with blood cancer worldwide.

What we do

• We create awareness of blood cancer diseases and treatments.
• We recruit stem cell donors to give those in need of a stem cell donation a second chance at life.
• We engage the public as well as companies to organize donor registration events.
• We raise funds to increase both the size and diversity of the worldwide pool of available stem cell donors.
• We help to improve blood cancer treatment – through our own research and state-of-the-art technology in our laboratory
• We maintain our donor relationship from day one of registration until stem cell donation.

SCIENCE AND RESEARCH

Scientific research is vital in helping to understand the treatment of blood cancer and improve the survival rate of patients. DKMS performs and supports research projects and quality programs on an international level, in order to optimize our work and improve the outcome for those in need of a stem cell donation.

 

Quality programs are used to ensure the continuous development and improvement in both the quality and the quantity of potential donors registered with DKMS. We are committed to efficiency and finding a matching donor for everyone in need of a stem cell donation as quickly as possible. Optimizing the quality of donor data is therefore one of our top priorities. By developing our own search algorithm, the Hap-E Search (Haplotype-Enhanced Search), we use patient findings to identify potential donors, identify suitable mismatch donors (with slight deviations in matching tissue characteristics) and enable automated searches. Other DKMS quality programs include the new typing of old donor data at our own expense, the targeted search for replacement donors and the ancestry program – which is used to find donors with rare combinations of tissue characteristics.

 

The Clinical Trials Unit (CTU) was founded in 2013 in Dresden, Germany, with the goal of promoting innovative research in the field of blood cancer. The department supports and performs research projects in order to help understand the implications of blood cancer treatment and improve the outcome for patients. Fundamental research, as well as international and interdisciplinary collaboration, is essential for this purpose.

Working for DKMS

The DKMS group is the world’s largest international network of donor centers and grows steadily every year. Our goal is to find a matching donor for everyone in need of a stem cell donation. In addition to donor recruitment activities, we improve the quality and quantity of available donors and support innovative research and projects. In order to achieve our goals, we need support in the fight against blood cancer.

If you are interested in a job please contact us.

DKMS Mechtild Harf Science Award

The DKMS Mechtild Harf Science Award is presented annually by the DKMS Foundation for Giving Life. The award recognizes the outstanding achievements of internationally renowned individuals in the field of stem cell transplantation.

 

2016

Katharina Fleischhauer (GER)

2015

John A. Hansen (USA)

2014

Richard J. O'Reilly (USA)

2013

Dennis L. Confer MD (USA)
Prof. Guido Lucarelli (Italien)

2011

Karl Blume (Deutschland)

2010

Prof. Dr. med. Dr. hc. mult. Theodor M. Fliedner (Deutschland)

2009

Rainer F. Storb (USA)

2008

Jan van Rood MD, PhD (Niederlande)

2007

Mary Horowitz MD,MS (USA)

2006

Prof. Dr. med. Hans-Jochem Kolb (Deutschland)

2005

Thomas E. Donnal MD (USA)

2004

Eliane Gluckmann MD (Frankreich)

2002

Efffie Wang Petersdorf MD (USA)

2001

Dr. Helmut Geiger (Deutschland)

 

One of the focuses of Fleischhauer’s research is the so-called HLA-DPB1 marker, which is used for improved matching of stem cell donor and patient. Through her research the physician was able to identify beneficial HLA-DPB1 combinations, and major blood stem cell registries recently started to use these findings to improve their search procedures. When searching for a matching donor, new filters can be applied to display donors whose HLA-DPB1 types work well with the respective patient’s types. DKMS has included the HLA-DPB1 type in its typing profile of newly registered donors since 2013.

 

John A. Hansen has been instrumental in the success and effectiveness of stem cell transplantation for blood cancer patients, in particular with regard to our understanding of the impact of genetic variations within the major histocompatibility complex (MHC complex) on the success of transplant. He has furthermore conducted clinical studies to analyze the role of genes that are crucially involved in the regulation of cellular immune responses.

Other ways to help

There are many ways to support our fight against blood cancer.

Register as a stem cell donor. You may save someone's life.

Follow us on social networks and share our appeals.